Top

Published in:

01-09-2016 | Original Article

VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice

Authors: Ming Sun, Yue Li, Zhe Yuan, Wuxun Lu, Guobin Kang, Wenjin Fan, Qingsheng Li

Published in: Archives of Virology | Issue 9/2016

Abstract

Broadly neutralizing antibodies (bNAbs) represent a new generation of antiviral agents for the prevention and treatment of human immunodeficiency virus 1 (HIV-1) infection. A better understanding of the in vivo efficacy of HIV-1 bNAbs, such as VRC01, in preventing mucosal transmission of HIV-1 has important implications for HIV-1 vaccine design. In this study, we evaluated the efficacy of passively transferred VRC01 antibody in preventing HIV-1 vaginal and rectal transmission in humanized bone marrow/liver/thymus mice (hu-BLT mice). Mice were subcutaneously injected with VRC01 IgG, and 24 hours later, they were challenged intravaginally or intrarectally with HIV-1Ada. All hu-BLT mice receiving VRC01 IgG antibody were aviremic at 2 weeks after intravaginal (n = 3) or intrarectal (n = 6) challenge as measured by quantitative real-time RT-PCR. In contrast, mice receiving control IgG all became infected. By 5 and 6 weeks post-challenge, some of VRC01 aviremic mice in both the intravaginal and intrarectal challenge groups became viremic. Our results suggest that VRC01 antibody can be protective against HIV-1 vaginal and rectal transmission; however, a single administration of VRC01 cannot completely prevent mucosal infection.

Available only for authorised users

Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J et al (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636–640CrossRefPubMed

Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, Goss JL et al (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285–289CrossRefPubMedPubMedCentral

Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS et al (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856–861CrossRefPubMedPubMedCentral

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien J-P et al (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466–470CrossRefPubMedPubMedCentral

Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TYK et al (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633–1637CrossRefPubMedPubMedCentral

Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS et al (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406–412

Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H et al (2011) Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334:1289–1293CrossRefPubMedPubMedCentral

McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, Khayat R et al (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336–343CrossRefPubMedPubMedCentral

Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF et al (2012) Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci 109:E3268–E3277CrossRefPubMedPubMedCentral

10.

Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S et al (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492:118–122CrossRefPubMed

11.

Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM et al (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5:0008805CrossRef

12.

Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q et al (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9:343–346CrossRefPubMed

13.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN et al (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:15CrossRef

14.

Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G et al (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84:1302–1313CrossRefPubMed

15.

Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D et al (1999) Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73:4009–4018PubMedPubMedCentral

16.

Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE et al (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207–210CrossRefPubMed

17.

Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E et al (2009) A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods 343:65–67CrossRefPubMed

18.

Moldt B, Rakasz EG, Schultz N, Chan-Hui P-Y, Swiderek K, Weisgrau KL et al (2012) Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 109:18921–18925CrossRefPubMedPubMedCentral

19.

Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang Z-Y et al (2015) Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J Virol 89:5895–5903CrossRefPubMedPubMedCentral

20.

Veselinovic M, Preston Neff C, Mulder LR, Akkina R (2012) Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 432:505–510CrossRefPubMedPubMedCentral

21.

Hatziioannou T, Evans DT (2012) Animal models for HIV/AIDS research. Nat Rev Microbiol 10:852–867CrossRefPubMedPubMedCentral

22.

Evans DT, Silvestri G (2013) Nonhuman primate models in AIDS research. Curr Opin HIV AIDS 8:255–261PubMedPubMedCentral

23.

Deruaz M, Luster AD (2013) BLT humanized mice as model to study HIV vaginal transmission. J Infect Dis 208(Suppl 2):S131–S136CrossRefPubMedPubMedCentral

24.

Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA et al (2006) Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 12:1316–1322CrossRefPubMed

25.

Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, Wege AK et al (2007) Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 204:705–714CrossRefPubMedPubMedCentral

26.

Brehm MA, Shultz LD, Luban J, Greiner DL (2013) Overcoming current limitations in humanized mouse research. J Infect Dis 208:S125–S130CrossRefPubMedCentral

27.

Zhou T, Georgiev I, Wu X, Yang Z-Y, Dai K, Finzi A et al (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811–817CrossRefPubMedPubMedCentral

28.

Wu X, Zhang Z, Schramm Chaim A, Joyce MG, Do Kwon Y, Zhou T et al (2015) Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell 161:470–485CrossRefPubMedPubMedCentral

29.

Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C et al (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593–1602CrossRefPubMedPubMedCentral

30.

Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P et al (2013) Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39:245–258CrossRefPubMedPubMedCentral

31.

Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME et al (2015) Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol 182:289–301CrossRefPubMed

32.

Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P et al (2015) Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med 7:319ra206–319ra206CrossRefPubMed

33.

Wang LX, Kang G, Kumar P, Lu W, Li Y, Zhou Y et al (2014) Humanized-BLT mouse model of Kaposi’s sarcoma-associated herpesvirus infection. Proc Natl Acad Sci USA 111:3146–3151CrossRefPubMedPubMedCentral

34.

Li Q, Tso FY, Kang G, Lu W, Li Y, Fan W et al (2015) Early initiation of antiretroviral therapy can functionally control productive HIV-1 infection in humanized-BLT mice. J Acquir Immune Defic Syndr 69:519–527CrossRefPubMed

35.

Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A et al (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439–1452CrossRefPubMed

36.

Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, Xu Z et al (2011) Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 121:2401–2412CrossRefPubMedPubMedCentral

37.

Lee FH, Mason R, Welles H, Learn GH, Keele BF, Roederer M et al (2015) Breakthrough virus neutralization resistance as a correlate of protection in a nonhuman primate heterologous simian immunodeficiency virus vaccine challenge study. J Virol 89:12388–12400PubMedPubMedCentral

38.

Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS et al (2014) Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 88:12669–12682CrossRefPubMedPubMedCentral

39.

Mascola JR (2002) Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20:1922–1925CrossRefPubMed

40.

Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481:81–84CrossRef

41.

Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS et al (2014) Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 20:296–300CrossRefPubMedPubMedCentral

42.

Della-Porta AJ, Westaway EG (1978) A multi-hit model for the neutralization of animal viruses. J Gen Virol 38:1–19CrossRefPubMed

Title: VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice
Authors: Ming Sun
Yue Li
Zhe Yuan
Wuxun Lu
Guobin Kang
Wenjin Fan
Qingsheng Li
Publication date: 01-09-2016
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 9/2016
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-016-2942-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2016

Impact of oseltamivir use on the reduction of complications in patients with influenza: a prospective study

Complete genome sequence of a novel sub-subgenotype 2.1g isolate of classical swine fever virus from China

Experimental infection with non-cytopathic bovine viral diarrhea virus 1 in mice induces inflammatory cell infiltration in the spleen

Detection and characterization of a novel genotype of porcine astrovirus 4 from nasal swabs from pigs with acute respiratory disease

Analysis of the genome sequence of the pathogenic Muscovy duck parvovirus strain YY reveals a 14-nucleotide-pair deletion in the inverted terminal repeats

Evidence for wild waterfowl origin of H7N3 influenza A virus detected in captive-reared New Jersey pheasants

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page